Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence
Cathrin Rohleder, Juliane Müller, Bettina Lange, et al.
Frontiers in Pharmacology (2016) Vol. 7
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials
Edward Chesney, Dominic Oliver, Alastair Green, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 11, pp. 1799-1806
Open Access | Times Cited: 221
Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science
Eric P. Baron
Headache The Journal of Head and Face Pain (2018) Vol. 58, Iss. 7, pp. 1139-1186
Closed Access | Times Cited: 211
Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review
Jerome Sarris, Justin Sinclair, Diana Karamacoska, et al.
BMC Psychiatry (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 201
A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders
Keane Lim, Yuen Mei See, Jimmy Lee
Clinical Psychopharmacology and Neuroscience (2017) Vol. 15, Iss. 4, pp. 301-312
Open Access | Times Cited: 147
Cannabidiol (CBD) use in psychiatric disorders: A systematic review
Stefania Bonaccorso, A Ricciardi, Caroline Zangani, et al.
NeuroToxicology (2019) Vol. 74, pp. 282-298
Open Access | Times Cited: 142
A review of methods for the chemical characterization of cannabis natural products
Allegra Leghissa, Zacariah L. Hildenbrand, Kevin A. Schug
Journal of Separation Science (2017) Vol. 41, Iss. 1, pp. 398-415
Closed Access | Times Cited: 120
The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder
Yann Chye, Erynn Christensen, Nadia Solowij, et al.
Frontiers in Psychiatry (2019) Vol. 10
Open Access | Times Cited: 119
A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome
Helen Heussler, Jonathan Cohen, Natalie Silove, et al.
Journal of Neurodevelopmental Disorders (2019) Vol. 11, Iss. 1
Open Access | Times Cited: 91
Cannabidiol induces autophagy via ERK1/2 activation in neural cells
Talita Aparecida de Moraes Vrechi, Anderson H.F.F. Leão, Ingrid B. M. Morais, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 55
Nanoformulations as a strategy to overcome the delivery limitations of cannabinoids
T. Srinivasa Reddy, Roby Zomer, Nitin Mantri
Phytotherapy Research (2023) Vol. 37, Iss. 4, pp. 1526-1538
Open Access | Times Cited: 39
THC and CBD: Villain versus Hero? Insights into Adolescent Exposure
Nicholas Pintori, Francesca Caria, Maria Antonietta De Luca, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5251-5251
Open Access | Times Cited: 28
Cannabidiol regulates apoptosis and autophagy in inflammation and cancer: A review
Ze Fu, Peng-yue Zhao, Xing-Peng Yang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 25
The endocannabinoid system as a target for addiction treatment: Trials and tribulations
Matthew E. Sloan, Joshua L. Gowin, Vijay A. Ramchandani, et al.
Neuropharmacology (2017) Vol. 124, pp. 73-83
Closed Access | Times Cited: 85
Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms
Claudia Calpe-López, María Pilar García-Pardo, M.A. Aguilar
Molecules (2019) Vol. 24, Iss. 14, pp. 2583-2583
Open Access | Times Cited: 70
Development of a validated method for the qualitative and quantitative analysis of cannabinoids in plant biomass and medicinal cannabis resin extracts obtained by super-critical fluid extraction
Aaron Elkins, Myrna A. Deseo, Simone Rochfort, et al.
Journal of Chromatography B (2019) Vol. 1109, pp. 76-83
Closed Access | Times Cited: 65
Effects of non‐euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice
Fabio Arturo Iannotti, Ester Pagano, Aniello Schiano Moriello, et al.
British Journal of Pharmacology (2018) Vol. 176, Iss. 10, pp. 1568-1584
Open Access | Times Cited: 64
Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis
Aisling O’Neill, Robin Wilson, Grace Blest‐Hopley, et al.
Psychological Medicine (2020) Vol. 51, Iss. 4, pp. 596-606
Closed Access | Times Cited: 63
Motor neuron development in zebrafish is altered by brief (5-hr) exposures to THC (∆9-tetrahydrocannabinol) or CBD (cannabidiol) during gastrulation
Kazi T. Ahmed, Md Ruhul Amin, Parv Shah, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 59
The Impact of Cannabidiol on Human Brain Function: A Systematic Review
Albert Batalla, Julian Bos, Amber Postma, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 48
Δ-9-Tetrahydrocannabinol and Cannabidiol produce dissociable effects on prefrontal cortical executive function and regulation of affective behaviors
Hanna J. Szkudlarek, Sagar Desai, Justine Renard, et al.
Neuropsychopharmacology (2018) Vol. 44, Iss. 4, pp. 817-825
Open Access | Times Cited: 51
Prolonged Cannabidiol Treatment Lacks on Detrimental Effects on Memory, Motor Performance and Anxiety in C57BL/6J Mice
Eva Maria Schleicher, Frederik Wilhelm Ott, Melanie Müller, et al.
Frontiers in Behavioral Neuroscience (2019) Vol. 13
Open Access | Times Cited: 50
Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia
Fernanda Fiel Peres, Mariana Cepollaro Diana, Raquel Levin, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 48
The ‘entourage effect’ or ‘hodge-podge hashish’: the questionable rebranding, marketing, and expectations of cannabis polypharmacy
Peter S. Cogan
Expert Review of Clinical Pharmacology (2020) Vol. 13, Iss. 8, pp. 835-845
Closed Access | Times Cited: 48
A Survey of Cannabis Acute Effects and Withdrawal Symptoms: Differential Responses Across User Types and Age
Michelle Sexton, Carrie Cuttler, Laurie K. Mischley
The Journal of Alternative and Complementary Medicine (2018) Vol. 25, Iss. 3, pp. 326-335
Open Access | Times Cited: 47
Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature
Nicole Tartaglia, Marcel O. Bonn‐Miller, Randi J. Hagerman
Cannabis and Cannabinoid Research (2019) Vol. 4, Iss. 1, pp. 3-9
Open Access | Times Cited: 47
Page 1 - Next Page

Scroll to top